The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 24, 2013

Filed:

Oct. 19, 2010
Applicants:

Satoshi Obika, Osaka, JP;

Yoshiyuki Hari, Osaka, JP;

Tetsuya Kodama, Osaka, JP;

Aiko Yahara, Osaka, JP;

Masaru Nishida, Osaka, JM;

Inventors:

Satoshi Obika, Osaka, JP;

Yoshiyuki Hari, Osaka, JP;

Tetsuya Kodama, Osaka, JP;

Aiko Yahara, Osaka, JP;

Masaru Nishida, Osaka, JM;

Assignee:

Osaka University, Osaka, JP;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); C07H 19/00 (2006.01); C07H 19/02 (2006.01);
U.S. Cl.
CPC ...
Abstract

It is an object of the present invention to provide a novel molecule for antisense therapies which is not susceptible to nuclease degradation in vivo and has a high binding affinity and specificity for the target mRNAs and which can efficiently regulate expression of specific genes. The novel artificial nucleoside of the present invention has an amide bond introduced into a bridge structure of 2',4′-BNA/LNA. The oligonucleotide containing the 2′,4′-bridged artificial nucleotide has a binding affinity for a single-stranded RNA comparable to known 2′,4′-BNA/LNA and has an increased nuclease resistance over LNA. Particularly, it is expected to be applied to nucleic acid drugs because of its much stronger binding affinity for single-stranded RNAs than S-oligo's affinity.


Find Patent Forward Citations

Loading…